用于肝细胞癌系统治疗选择的多达七个标准。
Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma.
机构信息
Department of Internal Medicine, NYU Grossman School of Medicine, New York, NY 10016, United States.
Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
出版信息
World J Gastroenterol. 2022 Jun 21;28(23):2561-2568. doi: 10.3748/wjg.v28.i23.2561.
Abstract
Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease. The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients. We will focus on "the up to seven" criteria and its utility in selecting systemic therapy.
摘要
巴塞罗那临床肝癌（BCLC）中期肝细胞癌是一种异质性疾病。在该疾病阶段，经动脉化疗栓塞被作为一线治疗方法。系统治疗的最新进展甚至在晚期疾病中也显著改善了预后。在 BCLC 中期疾病中使用系统治疗在某些患者中可能具有治疗益处。我们将重点介绍“最多七个”标准及其在选择系统治疗中的应用。
相似文献
1
Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma.用于肝细胞癌系统治疗选择的多达七个标准。
World J Gastroenterol. 2022 Jun 21;28(23):2561-2568. doi: 10.3748/wjg.v28.i23.2561.
2
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用：巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
3
Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.原发性肝细胞癌患者的肿瘤分期及初始治疗方式分布
Clin Transl Oncol. 2017 Jul;19(7):891-897. doi: 10.1007/s12094-017-1621-6. Epub 2017 Feb 3.
4
Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.巴塞罗那临床肝癌分期0/A期切除术后复发性肝细胞癌经动脉化疗栓塞术与射频消融术的回顾性对比研究
J Vasc Interv Radiol. 2016 Dec;27(12):1829-1836. doi: 10.1016/j.jvir.2016.06.010. Epub 2016 Aug 21.
5
Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.传统碘油经动脉化疗栓塞术治疗肝细胞癌：当代单中心临床结局回顾
AJR Am J Roentgenol. 2016 Mar;206(3):645-54. doi: 10.2214/AJR.15.14758.
6
Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.经动脉放射性栓塞与化疗栓塞治疗肝细胞癌（TRACE）：一项随机对照试验的研究方案。
Trials. 2012 Aug 23;13:144. doi: 10.1186/1745-6215-13-144.
7
Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.优化BCLC B期肝细胞癌患者的管理：现代手术切除作为经动脉化疗栓塞的可行替代方案。
Eur J Surg Oncol. 2015 Sep;41(9):1153-61. doi: 10.1016/j.ejso.2015.05.023. Epub 2015 Jun 12.
8
Therapeutic advances for patients with intermediate hepatocellular carcinoma.中危肝细胞癌患者的治疗进展。
J Cell Physiol. 2019 Aug;234(8):12116-12121. doi: 10.1002/jcp.28019. Epub 2019 Jan 15.
9
Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.肝切除术与经肝动脉化疗栓塞术治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的比较。
Hepatol Int. 2018 Sep;12(5):417-428. doi: 10.1007/s12072-018-9888-4. Epub 2018 Aug 2.
10
New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.新的中期亚分类方法用于接受经动脉化疗栓塞治疗的肝细胞癌患者。
Liver Int. 2017 Dec;37(12):1861-1868. doi: 10.1111/liv.13487. Epub 2017 Jun 26.
引用本文的文献
1
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.免疫检查点抑制剂联合疗法在可切除和不可切除、适合栓塞治疗的肝细胞癌中的作用
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.
2
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric.肝细胞癌患者肝移植选择标准的预后作用：综述与文献计量学分析
ILIVER. 2024 Feb 6;3(1):100077. doi: 10.1016/j.iliver.2024.100077. eCollection 2024 Mar.
3
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma.免疫微环境与血管内皮生长因子抑制在肝细胞癌中的作用
Int J Mol Sci. 2024 Dec 19;25(24):13590. doi: 10.3390/ijms252413590.
4
Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.经动脉化疗栓塞联合分子靶向药物加免疫检查点抑制剂治疗超出 up-to-seven 标准的不可切除肝细胞癌：倾向评分匹配分析。
Ann Med. 2024 Dec;56(1):2419993. doi: 10.1080/07853890.2024.2419993. Epub 2024 Nov 1.
5
Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌的多学科护理与多模式治疗方法
Adv Oncol. 2024 May;4(1):247-262. doi: 10.1016/j.yao.2024.02.002. Epub 2024 Feb 23.
6
PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.异常凝血酶原（PIVKA-II）联合肿瘤负荷评分预测 AFP 阴性肝癌患者肝切除术后的长期预后。
Cancer Med. 2024 Jan;13(1):e6835. doi: 10.1002/cam4.6835. Epub 2023 Dec 21.
本文引用的文献
1
Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide.识别将从经动脉化疗栓塞（TACE）治疗中获益的患者的当前策略及未来方向：实用分步指南
J Hepatocell Carcinoma. 2021 May 13;8:403-419. doi: 10.2147/JHC.S285735. eCollection 2021.
2
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.局部区域治疗在肝癌的分子和免疫治疗时代。
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293-313. doi: 10.1038/s41575-020-00395-0. Epub 2021 Jan 28.
3
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
4
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.老龄化社会中肝细胞癌全身治疗的最新进展：2020年更新
Liver Cancer. 2020 Dec;9(6):640-662. doi: 10.1159/000511001. Epub 2020 Nov 17.
5
Management of patients with intermediate stage hepatocellular carcinoma.中期肝细胞癌患者的管理
Ther Adv Med Oncol. 2020 Nov 5;12:1758835920970840. doi: 10.1177/1758835920970840. eCollection 2020.
6
Standardization of conventional chemoembolization for hepatocellular carcinoma.规范肝细胞癌的常规化疗栓塞。
Ann Hepatol. 2021 May-Jun;22:100278. doi: 10.1016/j.aohep.2020.10.006. Epub 2020 Oct 29.
7
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.纳武利尤单抗联合伊匹木单抗治疗索拉非尼治疗后晚期肝细胞癌患者的疗效和安全性：CheckMate 040 随机临床试验。
JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12.
8
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
9
Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.评价肝细胞癌患者经动脉化疗栓塞治疗抵抗。
PLoS One. 2020 Mar 4;15(3):e0229696. doi: 10.1371/journal.pone.0229696. eCollection 2020.
10
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.一种针对高肿瘤负荷中期肝细胞癌的新治疗选择：初始仑伐替尼治疗后序贯选择性经动脉化疗栓塞术
Liver Cancer. 2019 Oct;8(5):299-311. doi: 10.1159/000502905. Epub 2019 Sep 18.
Zotero 插件